Activest Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Activest Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.9K	Sell	100 -83	-45%	-$12.3K	﹤0.01%	479
2026 Q1	$24.1K	Buy	183 +11	+6%	+$1.46K	﹤0.01%	477
2025 Q4	$24.4K	Buy	172 +169	+5,633%	+$24.5K	﹤0.01%	460
2025 Q3	$421	Hold	3	–	–	﹤0.01%	976
2025 Q2	$377	Buy	+3	New	+$344	﹤0.01%	905
2023 Q1	–	Sell	-43	Closed	-$5.14K	–	455
2022 Q4	$5.14K	Sell	43 -17	-28%	-$1.99K	﹤0.01%	355
2022 Q3	$6K	Buy	+60	New	+$6.09K	﹤0.01%	340

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Activest Wealth Management's NBIX Position: Q2 2026 in Review

Activest Wealth Management reduced its Neurocrine Biosciences (NBIX) stake by 45% in Q2 2026, selling an estimated $12.3K and leaving 100 shares worth $16.9K. The position accounts for ﹤0.01% of the portfolio, ranked #479.

Activest Wealth Management first reported a position in NBIX in Q3 2022 and has held it in 7 quarters since. The position peaked at $24.4K in Q4 2025. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Activest Wealth Management held 100 shares of Neurocrine Biosciences worth $16.9K as of Q2 2026.
Activest Wealth Management sold 83 Neurocrine Biosciences shares in Q2 2026, an estimated $12.3K.
Neurocrine Biosciences made up ﹤0.01% of Activest Wealth Management's portfolio in Q2 2026, its #479 holding.
Activest Wealth Management first reported a position in Neurocrine Biosciences in Q3 2022 and has held it in 7 quarters since.
Activest Wealth Management's Neurocrine Biosciences position peaked at $24.4K in Q4 2025.
779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Activest Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.